Our news

Aurum Biosciences Receives £670k in New Equity Funding Round Aurum Biosciences Ltd (Aurum) has raised approximately £670k as part of a new round of equity funding. This funding...

ABL-101 Found to be a Promising Candidate for Use in Inflammation Imaging Aurum in collaboration with an MRI research group based in Lausanne, Switzerland, led by Dr Ruud van...

Aurum Biosciences Has Second Patent Granted in the EU Aurum Biosciences are pleased to announce that that they have been granted a second EU patent for their ABL-101 imaging...

Aurum Attending 2018 Bio-Europe Partnering Conference Aurum Biosciences Ltd (olliet39.sg-host.com/), a clinical stage company which has developed an innovative technology that...

Aurum Publishes Paper on ABL-101 Technology Aurum Biosciences Ltd, in collaboration with colleagues at the University of Glasgow and NHS Greater Glasgow and Clyde, have had a...

Aurum Attending Bio International Convention   Aurum Biosciences Ltd (olliet39.sg-host.com/), a clinical stage company which has developed an innovative technology that has...

Aurum Biosciences Attending Biotech Showcase in San Francisco Aurum Biosciences Ltd (olliet39.sg-host.com/), a company which has developed an innovative technology with the...

Aurum Biosciences receives UK regulatory approval for a Phase 2 trial of ABL-101 in stroke patients Aurum Biosciences Ltd (olliet39.sg-host.com/), a Glasgow-based...

Aurum Biosciences is attending and presenting a company showcase at this years Biotrinity event in London, which is being held today and tomorrow (9th and 10th May 2017). Aurum...

Aurum Biosciences Presenting at Official Opening of Imaging Centre of Excellence. Aurum Biosciences' Dr Celestine Santosh is an invited speaker at the official opening of the...